A Phase 1 study of Ac-225 Rosopatamab Tetraxetan in Prostate Cancer

Study Description

A Study Evaluating a New Radioactive Therapy for Prostate Cancer

Study Details

Registry ID:

NCT06549465

Conditions:

PSMA PET-Positive Castration-Resistant Prostate Cancer

Phase:

Phase 2

Target Enrollment:

93 participants

Start Date:

August 6, 2024

Age Range:

18–999 years

Gender:

Male

Healthy Volunteers:

No

Study Locations (10 sites)

• Dana-Farber Cancer Institute
  Boston, MassachusettsUnited States, United States
• Laura & Isaac Perlmutter Cancer Center
  New York, New YorkUnited States, United States
• Memorial Sloan Kettering Cancer Center
  New York, New YorkUnited States, United States
• New York Presbyterian/Weill Cornell Medical Center
  New York, New YorkUnited States, United States
• Duke University Medical Center
  Durham, North CarolinaUnited States, United States
• The Cleveland Clinic Foundation
  Cleveland, OhioUnited States, United States
• Washington University in St. Louis
  Saint Louis, MissouriUnited States, United States
• Washington University in St. Louis
  St Louis, MissouriUnited States, United States
• X Cancer Omaha / Urology Cancer Center
  Omaha, NebraskaUnited States, United States
• University of California San Diego
  San Diego, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →